Americas Small Cap Research Summary

This Barclays summary reviews recent clinical data and investment ratings for Alpha Tau, Immunome, and Vir Biotechnology.

Key Takeaways

• 1.Alpha Tau's Alpha DaRT shows potential in tumor-agnostic combinations, particularly in pancreatic ductal adenocarcinoma (PDAC).
• 2.Immunome's ASCO RINGSIDE data supports its preferential profile over Nirogacestat for potential approval.
• 3.Vir Biotechnology reports durable and superior efficacy in Hepatitis Delta Virus (HDV) based on 96-week SOLSTICE data.

Table of Contents

• Company Research
• Alpha Tau: ASCO PDAC Data Highlights Alpha DaRT Potential
• Immunome: ASCO RINGSIDE Data Continues to Support Potential Approval
• Vir Biotechnology: SOLSTICE 96-Week Data Highlights Durable & Superior Efficacy in HDV
• Analyst(s) Certification(s)
• Important Disclosures
• Availability of Disclosures
• Risk Disclosure(s)
• Guide to the Barclays Fundamental Equity Research Rating System
• Industry View
• Distribution of Ratings
• Guide to the Barclays Research Price Target
• Types of investment recommendations produced by Barclays Equity Research
• Disclosure of other investment recommendations produced by Barclays Equity Research
• Legal entities involved in producing Barclays Research
• Disclaimer

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial